Girish S. Kulkarni

Girish S. Kulkarni

Auto-generated profile, based on publicly available information

Girish S. Kulkarni

Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Annals of Oncology
Verified
Journal Article
Closed access
DMD.E. Magee
D.E. Magee
AHA.E. Hird
A.E. Hird
ZKZ. Klaassen
Z. Klaassen
SSS.S. Sridhar
S.S. Sridhar
RNR.K. Nam
R.K. Nam
GKG.S. Kulkarni
G.S. Kulkarni

9 July 2013 in Cancer
Verified
Journal Article
Open access
PDF file
GKGirish S. Kulkarni
Girish S. Kulkarni
DUDavid R. Urbach
David R. Urbach
PAPeter C. Austin
Peter C. Austin
NFNeil E. Fleshner
Neil E. Fleshner
ALAndreas Laupacis
Andreas Laupacis
BACKGROUND: Hospital and surgeon (provider) volume are associated with clinically significant outcomes for many types of surgery. Volume‐outcome studies in patients undergoing radical cystectomy for bladder cancer have focused primarily on postoperative mortality. In the current study, the authors assessed the effect of cystectomy provider volume on long‐term mortality.METHODS: Using administrative databases, 2535 patients who underwent cystectomy by 199 surgeons in 90 hospitals in Ontario, Canada, between 1992 and 2004 were identified. The impact of provider volume on overall survival (OS) was assessed using Cox proportional hazards models fully adjusted for patient and tumor characteristics. Separate models were fit to examine the effect of surgeon and hospital volume. To confirm that the impact of volume on OS was independent of the effect of volume on short‐term mortality, analyses were repeated excluding those patients experiencing postoperative deaths.RESULTS: Of 2535 patients, 1796 (70.9%) died during the study period. Both higher hospital volume (hazards ratio [per unit increase in average annual number of procedures], 0.995; 95% confidence interval, 0.990‐1.000 [P = .044]) and higher surgeon volume (hazards ratio, 0.984; 95% confidence interval, 0.975‐0.994 [P = .002]) were found to be significantly associated with improved OS. Excluding post‐operative deaths did not alter the results. Further analyses revealed that the benefit of high volume was attained by receiving care from either high‐volume hospitals or high‐volume surgeons.CONCLUSIONS: High‐volume providers were associated with improved long‐term mortality rates compared with low‐volume providers. This finding was independent of the effect of volume on perioperative mortality, suggesting that provider volume effects continue to manifest long after surgery. Cancer 2013;119:3546–3554.. © 2013 American Cancer Society.

1 November 2018 in European Urology
Verified
Journal Article
Closed access
ZKZachary Klaassen
Zachary Klaassen
AKAshish M. Kamat
Ashish M. Kamat
WKWassim Kassouf
Wassim Kassouf
PGPaolo Gontero
Paolo Gontero
HVHumberto Villavicencio
Humberto Villavicencio
GKGirish S. Kulkarni
Girish S. Kulkarni

1 August 2021 in Radiology
Verified
Journal Article
Closed access
DDDominik Deniffel
Dominik Deniffel
GHGerard M. Healy
Gerard M. Healy
XDXin Dong
Xin Dong
SGSangeet Ghai
Sangeet Ghai
ESEmmanuel Salinas-Miranda
Emmanuel Salinas-Miranda
MHMasoom A. Haider
Masoom A. Haider
A strategy combining Prostate Imaging Reporting and Data System and prostate-specific antigen density was superior to MRI-based risk models in safely reducing unnecessary biopsies without missing c... Background In validation studies, risk models for clinically significant prostate cancer (csPCa; Gleason score ≥3+4) combining multiparametric MRI and clinical factors have demonstrated poor calibr...

1 June 2022 in European Urology Open Science
Verified
Journal Article
Open access
GKGirish S. Kulkarni
Girish S. Kulkarni
LLLothar Lilge
Lothar Lilge
MNMichael Nesbitt
Michael Nesbitt
RDRoger J. Dumoulin-White
Roger J. Dumoulin-White
AMArkady Mandel
Arkady Mandel
MJMichael A.S. Jewett
Michael A.S. Jewett
A phase 1b study of photosensitizer TLD-1433–mediated photodynamic therapy (PDT) was performed in bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) patients. The primary objectives were safety and tolerability of PDT, with secondary objectives of (1) pharmacokinetic (PK) properties of TLD-1433 and (2) efficacy, as evaluated by recurrence-free survival and complete response (CR) at 90 and 180 d for patients treated at the maximum recommended starting dose (0.35 mg/cm2 bladder surface area) and the therapeutic dose (0.70 mg/cm2). Six BCG-unresponsive patients were enrolled in an open-label, single-arm, dose-escalating study of PDT. TLD-1433 was instilled intravesically for 60 min preoperatively. PDT was performed under general anesthesia using intravesically delivered irradiation of the bladder wall with green light (520 nm) to a dose of 90 J/cm2. Patients were followed by standard cystoscopy and cytology for up to 18 mo to assess time to recurrence. PDT was well tolerated by all patients. All patients experienced at least one grade ≤2 adverse event (AE). There were no patient deaths or light sensitivity reactions. The most common AE was moderate bladder irritability, which resolved within the first weeks after treatment. AEs were independent of the TLD-1433 dose. TLD-1433 was cleared in the urine and from the plasma within 24 and 72 h, respectively. Of three patients treated at the therapeutic dose, two achieved a CR at 180 d, which was durable at 18 mo. The other patient was diagnosed with metastatic disease at 138 d. PDT with TLD-1433 appears safe for the treatment of BCG-unresponsive NMIBC. Early efficacy signals from full-dose photosensitizer are encouraging and warrant phase 2 trial investigation. The safety and PK results obtained support the potential for administration of consecutive PDT treatments as required. Photodynamic therapy with TLD-1433 appears to be safe and effective for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer.

1 July 2021 in European Urology Focus
Verified
Journal Article
Closed access
JKJethro C.C. Kwong
Jethro C.C. Kwong
LMLouise C. McLoughlin
Louise C. McLoughlin
MHMasoom Haider
Masoom Haider
MGMitchell G. Goldenberg
Mitchell G. Goldenberg
LELauren Erdman
Lauren Erdman
GKGirish S. Kulkarni
Girish S. Kulkarni